Scientists present current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec.
Categories
Recent Posts
- Guest Voice: Navigating the windy road of rare disease specialists
- Capricor Therapeutics Announces New PDUFA Date for Deramiocel
- MDA 2026: Keynote speaker to MDA community: ‘Your voice is powerful’
- Capricor announces the FDA to review deramiocel for Duchenne by August 2026
- Edgewise Therapeutics, a CureDuchenne funded company, announces positive long-term Sevasemten data in Becker muscular dystrophy patients.
Archive
- March 2026
- February 2026
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024